ATG16L1 and non-small cell lung carcinoma: Indeed, ATG16‐L1 is a critical regulator of autophagy, and the role of autophagy in response to EGFR‐TKI treatment remains a subject of debate in NSCLC with either cytotoxic or cytoprotective properties [34, 35, 36, 37, 38, 44].